BRIEF published on 07/21/2025 at 08:38, 11 months 5 days ago Cherry SE Revises 2025 Financial Forecast EBITDA Margin Cherry SE Financial Forecast Munich 2025 Sales
BRIEF published on 07/21/2025 at 08:38, 11 months 5 days ago Cherry SE révise ses prévisions financières pour 2025 Marge EBITDA Munich Prévisions Financières Cerise SE Ventes 2025
PRESS RELEASE published on 07/21/2025 at 08:33, 11 months 5 days ago EQS-Adhoc: Cherry SE: Forecast update for the 2025 financial year Cherry SE updates its forecast for the 2025 financial year following the publication of preliminary second quarter figures, expecting consolidated sales of EUR 100-115 million and adjusted EBITDA margin of 0-2% EBITDA Margin Cherry SE Sales Forecast Forecast Update 2025 Financial Year
BRIEF published on 07/18/2025 at 17:20, 11 months 7 days ago Cherry SE's 2025 Half-Year Results Impacted by Strategic Shift Inventory Management Cherry SE Revenue Decline Strategic Realignment 2025 Financial Results
BRIEF published on 07/18/2025 at 17:20, 11 months 7 days ago Les résultats semestriels 2025 de Cherry SE impactés par un changement stratégique Baisse Des Revenus Gestion Des Stocks Réalignement Stratégique Cerise SE Résultats Financiers 2025
PRESS RELEASE published on 07/18/2025 at 17:15, 11 months 7 days ago Cherry SE: Preliminary half-year results 2025 shaped by strategic realignment Cherry SE announces preliminary half-year results for 2025 with revenue of EUR 46.0 million and strategic realignment focusing on profitability EBITDA Margin Cherry SE Preliminary Results Strategic Realignment Fiscal Year 2025
BRIEF published on 07/18/2025 at 17:13, 11 months 7 days ago Cherry SE Reports Preliminary Q2 2025 Figures Revenue EBITDA Margin Cherry SE Preliminary Figures Q2 2025
BRIEF published on 07/18/2025 at 17:13, 11 months 7 days ago Cherry SE publie ses chiffres préliminaires du deuxième trimestre 2025 Marge D'EBITDA Chiffres Préliminaires Cerise SE Revenu T2 2025
PRESS RELEASE published on 07/18/2025 at 17:08, 11 months 7 days ago EQS-Adhoc: Cherry SE: Preliminary figures for the second quarter of 2025 Cherry SE reports Q2 2025 revenue of EUR 20.7 million with -1.3% adjusted EBITDA margin, prompting review of full-year forecast. Details at ir.cherry.de Revenue Adjusted EBITDA Margin Cherry SE Forecast Q2 2025
BRIEF published on 05/28/2025 at 15:45, 1 year ago Cherry SE Completes Sale of Hygiene Peripherals Division Cherry SE Restructuring Contour Design Hygiene Peripherals Active Key
Published on 06/26/2026 at 14:05, 14 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 19 minutes ago Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 1 hour 19 minutes ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 01:40, 12 hours 39 minutes ago UraniumX Announces DTC Eligibility for U.S. Traded Shares
Published on 06/26/2026 at 14:00, 19 minutes ago Hong Kong celebrates surge of global enterprises driving investment and opportunities
Published on 06/26/2026 at 14:00, 19 minutes ago Bitcoin Group SE publishes 2025 Annual Report: Strategic realignment ensures future viability in the dynamic crypto market
Published on 06/26/2026 at 13:32, 47 minutes ago Porsche ranks number one in J.D. Power 2026 U.S. Initial Quality Study
Published on 06/26/2026 at 13:30, 48 minutes ago Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share
Published on 06/26/2026 at 13:30, 49 minutes ago AlphaESS Unveils Expanded Energy Storage Ecosystem for Europe at Intersolar 2026
Published on 06/26/2026 at 07:00, 7 hours 19 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 7 hours 19 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 18:45, 19 hours 34 minutes ago Avis Financier Semestriel SFCMC au 30 avril 2026
Published on 06/25/2026 at 18:30, 19 hours 49 minutes ago Avis financier semestriel SIEHM au 30 avril 2026
